Citalopram

Generic Name: Citalopram

Brand Names: Celexa, Ctp

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₂O

CAS Number: 59729-33-8

Unique Ingredient Identifier: 0DHU5B8D6V

Background: Citalopram is an antidepressant belonging to the class of selective serotonin-reuptake inhibitors (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs. Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition. Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors.

Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.

Indication: Citalopram is approved by the FDA for treating adults with major depressive disorder. It has also been used off-label to treat various diseases, including but not limited to sexual dysfunction, ethanol abuse, psychiatric conditions such as obsessive-compulsive disorder (OCD), social anxiety disorder, panic disorder, and diabetic neuropathy.

Associated Conditions: Alcohol Abuse, Anorexia Nervosa (AN), Binge Eating Disorder (BED), Bulimia Nervosa, Depression, Diabetic Neuropathies, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Separation Anxiety Disorder, Social Anxiety Disorder (SAD)

Associated Therapies: -

Clinical Trials

N-methylglycine (Sarcosine) Treatment for Depression

Phase 2

Completed

Conditions: Major Depressive Disorder
Depression
Major Depression

Interventions: Drug: sarcosine
Drug: citalopram

First Posted Date: 2009-09-15

Last Posted Date: 2011-07-12

Lead Sponsor: China Medical University Hospital

Target Recruit Count: 40

Registration Number: NCT00977353

Locations: 🇨🇳
Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan

Anxiety and Recurrent Abdominal Pain in Children

Phase 2

Completed

Conditions: Abdominal Pain
Anxiety

Interventions: Drug: Placebo
Drug: Citalopram

First Posted Date: 2009-08-19

Last Posted Date: 2020-06-11

Lead Sponsor: John V. Campo, M.D.

Target Recruit Count: 81

Registration Number: NCT00962039

Locations: 🇺🇸
The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

Phase 4

Terminated

Conditions: Major Depressive Disorder With Psychotic Features

Interventions: Drug: Quetiapine
Drug: escitalopram
Drug: Sertraline
Drug: Citalopram

First Posted Date: 2009-08-10

Last Posted Date: 2017-04-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 32

Registration Number: NCT00955474

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Citalopram for Agitation in Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease
Agitation

Interventions: Drug: placebo
Drug: citalopram

First Posted Date: 2009-05-12

Last Posted Date: 2014-06-27

Lead Sponsor: JHSPH Center for Clinical Trials

Target Recruit Count: 186

Registration Number: NCT00898807

Locations: 🇺🇸
Monroe Community Hospital, Rochester, New York, United States
🇺🇸
VA Palo Alto Health Care System, Palo Alto, California, United States
🇺🇸
University of Southern California Keck School of Medicine Memory and Aging Center, Los Angeles, California, United States

and more 5 locations